Trials / Completed
CompletedNCT04411628
A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19
A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it. Participation could last about 8 weeks and may include up to 15 visits in the hospital or the home.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3819253 | Administered IV. |
| DRUG | Placebo | Administered IV. |
Timeline
- Start date
- 2020-05-28
- Primary completion
- 2020-08-26
- Completion
- 2020-08-26
- First posted
- 2020-06-02
- Last updated
- 2021-11-12
- Results posted
- 2021-11-09
Locations
11 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04411628. Inclusion in this directory is not an endorsement.